Similarly, Yanishevski et al. (16) pointed out that MYCN-amplification in high-risk NB was associated with a better response of the primary tumor to neoadjuvant chemotherapy after analyzing data from 84 high-risk patients with NB. This evidence concerns the gene MYCN and neuroblastoma.